Inbiomotion, a spin-off from IRB Barcelona, developed a unique single-gene-based biomarker for the personalised adjuvant treatment of early-stage breast cancer patients. The study has compared the clinical efficacy of the proprietary MAFTEST® for the selection of patients for adjuvant bisphosphonate therapy with that of current clinical guidance.
The MAFTEST® assessments of the landmark clinical trials NSABP-B34 and AZURE showed its clinical value for the selection of individuals with early-stage breast cancer who can benefit from adjuvant clodronate treatment. The study shows that stratification of early-stage breast cancer patients according to MAF status reduces the risk of death and relapse in MAF-negative patients by 26% and 23%, respectively, compared to a 12% and 15% reduction in the risk of death or relapse seen with stratification by menopausal status, recommended by current ESMO and ASCO Clinical Guidelines.
The use of MAF status for selecting early-stage breast cancer patients for bisphosphonate treatment allows young premenopausal patients currently excluded by existing clinical guidance access to therapy.
For more information: https://www.irbbarcelona.org/en/news/institutional/irb-barcelona-spin-inbiomotion-validates-its-test-which-will-help-reduce
